Get the Stockscreener App
0.9433
7.52%
-0.0767
After Hours:
.92
-0.0233
-2.47%
Tiziana Life Sciences Ltd stock is traded at $0.9433, with a volume of 427.40K.
It is down -7.52% in the last 24 hours and down -17.97% over the past month.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
See More
Previous Close:
$1.02
Open:
$0.98
24h Volume:
427.40K
Relative Volume:
0.48
Market Cap:
$110.22M
Revenue:
-
Net Income/Loss:
$-13.73M
P/E Ratio:
-7.2562
EPS:
-0.13
Net Cash Flow:
$-3.92M
1W Performance:
-15.78%
1M Performance:
-17.97%
6M Performance:
-5.67%
1Y Performance:
+111.17%
1-Day Range:
$0.8762
$1.0299
1-Week Range:
$0.8762
$1.13
52-Week Range:
$0.41
$1.91
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
Name
Tiziana Life Sciences Ltd
Sector
Industry
Phone
-
Address
-
Compare TLSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
0.9433 | 110.22M | 0 | -13.73M | -3.92M | -0.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Dec-17-18 | Initiated | Laidlaw | Buy |
Tiziana Life Sciences Ltd Stock (TLSA) Latest News
TLSATiziana Life Sciences Ltd Com Latest Stock News & Market Updates - Stock Titan
Small cap wrap: Zero Candida, Midnight Sun Mining, Tiziana Life Sciences, Trust Stamp... - Proactive Investors
Tiziana Life Sciences begins patient dosing in Phase 2 MS trial at Johns Hopkins - Proactive financial news
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab In Phase 2 Multiple Sclerosis Clinical Trial - MarketScreener
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial - The Manila Times
Major Breakthrough: Johns Hopkins Launches Novel Nasal Treatment in Phase 2 MS Trial - Stock Titan
Tiziana Life Sciences begins dosing in trial of therapy for multiple sclerosis - Yahoo Finance
Small cap wrap: Northern Superior Resources, Tiziana Life Sciences, Alternus Clean Energy... - Proactive Investors
Multiple sclerosis Clinical Trials and Studies 2025: EMA, PDMA, - openPR
Tiziana Life Sciences begins dosing in Phase 2 trial for intranasal foralumab in SPMS - Proactive Investors
Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial - The Manila Times
Yale Launches Groundbreaking Intranasal MS Treatment Trial: Tiziana's Innovation in Focus - Stock Titan
Tiziana Life Sciences Ltd Files For Mixed Shelf Of Up To $250 MillionSEC Filing -March 24, 2025 at 05:22 pm EDT - Marketscreener.com
Tiziana Life Sciences CEO to present at 37th Annual ROTH Conference - Proactive Investors UK
Tiziana Life Sciences to Present at the 37th Annual Roth Conference - The Manila Times
Tiziana Life Sciences Reveals Growth Strategy at Major ROTH ConferenceKey Updates Expected - StockTitan
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule - The Manila Times
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Requirements - Nasdaq
Tiziana Life Sciences Regains Compliance With Nasdaq Listing Minimum Bid Price Rule - MENAFN.COM
Tiziana Life Sciences Regains Nasdaq Compliance, Secures Continued Listing - TipRanks
Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential - Simply Wall St
Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease - Informazione.it
Can Tiziana's Foralumab Enable Breakthroughs In Neuroinflammatory And Neurodegenerative Diseases? - RTTNews
Tiziana Life Sciences stock soars to 52-week high of $1.75 - Investing.com
Democrat-led states join legal fight over Trump's mass firings of federal workers -March 06, 2025 at 10:38 pm EST - Marketscreener.com
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) Stock Hits Multi-Month High After Filing a Key IND with the FDA - DRP Journal
Tiziana: Foralumab Drug Development Presses On With Additional EAP Enrollment - Seeking Alpha
Sector Update: Health Care -March 04, 2025 at 03:39 pm EST - Marketscreener.com
Tiziana submits FDA investigational new drug application - Proactive Investors UK
Tiziana Life Sciences Files New Drug Application for ALS Drug Candidate -March 04, 2025 at 09:03 am EST - Marketscreener.com
Tiziana Life Sciences Advances ALS Treatment with FDA IND Submission - TipRanks
Tiziana Life Sciences Files Investigational New Drug Application With FDA For ALS Phase 2 Clinical Trial - Marketscreener.com
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial - The Manila Times
Could This Intranasal Therapy Change ALS Treatment? Tiziana Seeks FDA Approval - StockTitan
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Significant Drop in Short Interest - Defense World
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - MSN
Why Tiziana Life Sciences Ltd (TLSA) is Skyrocketing So Far in 2025 - Insider Monkey
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
Tiziana stock jumps 12% on TBI drug study publication - MSN
Tiziana Life Sciences' lead candidate demonstrates favorable safety profile and clinical response - Proactive Investors UK
Market movers: Ideal Power, Tiziana Life Sciences, Medicus Pharma... - Proactive financial news
Tiziana Life Sciences nasal anti-CD3 therapy shows promise in treating traumatic brain injury, study reveals - Proactive Investors UK
Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury - The Manila Times
Can Tiziana's Nasal Therapy Revolutionize Traumatic Brain Injury Treatment? New Study Says Yes - StockTitan
Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive… - Informazione.it
Small cap headlines: Candel Therapeutics, Sintana Energy, Trust Stamp, Tiziana Life Sciences... - Proactive financial news
Tiziana Life Sciences nearing completion of long COVID study on foralumab - Proactive Investors UK
Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter - The Manila Times
Can This Nasal Therapy Solve Long COVID? Tiziana's Breakthrough Approach Targets Brain Inflammation - StockTitan
Tiziana Life Sciences Ltd Stock (TLSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):